Chemoprevention in Barrett's oesophagus

Best Practice and Research: Clinical Gastroenterology

Volumn 29, Issue 1, 2015, Pages 151-165

  Baruah, Anushka ^a   Buttar, Navtej S ^a  

^a Mayo Clinic   (United States)

Author keywords

Barrett's oesophagus(BO); Chemo preventive agents; Oesophageal adenocarcinoma(OAC); Surrogate endpoint markers(SEBs)

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BILE ACID; BIOLOGICAL MARKER; CARCINOGEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; URSODEOXYCHOLIC ACID;

BARRETT ESOPHAGUS; BILE REFLUX; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL STUDY; DIET; DRUG EFFECT; DRUG EFFICACY; DYSPLASIA; ENDOCRINE SYSTEM; EPIDEMIOLOGICAL DATA; EPIGENETICS; EPITHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS INJURY; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; IMMUNOSURVEILLANCE; INFLAMMATION; LIFESTYLE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH ACID; ADENOCARCINOMA; COMPLICATION; ESOPHAGEAL NEOPLASMS; INCIDENCE; PROCEDURES;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CHEMOPREVENTION; ESOPHAGEAL NEOPLASMS; HUMANS; INCIDENCE;

EID: 84925095928     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.12.003     Document Type: Review

References (114)

1. G.W. Falk A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus Gastroenterology 143 4 2012 917 926 e1
2. S.J. Spechler American gastroenterological association technical review on the management of Barrett's esophagus Gastroenterology 140 3 2011 e18 52 quiz e13
3. J. Akiyama Strategy for prevention of cancers of the esophagus Ann N. Y Acad Sci 1325 1 2014 108 126
4. M. Gupta Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US multicenter consortium Gastroenterology 145 1 2013 79 86 e1
5. G.A. Prasad Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus Gastroenterology 135 2 2008 370 379
6. M.F. Vaezi, and J.E. Richter Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus Surgery 117 6 1995 699 704
7. S.J. Spechler Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial J Am Med Assoc 285 18 2001 2331 2338
8. M.T. Caldwell Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus Br J Surg 82 5 1995 657 660
9. D. Nehra Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity Gut 44 5 1999 598 602
10. S.J. Sontag The medical management of reflux esophagitis. Role of antacids and acid inhibition Gastroenterol Clin North Am 19 3 1990 683 712
11. J. Theisen Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids J Gastrointest Surg 4 1 2000 50 54
12. S.R. Goldstein Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen Carcinogenesis 18 11 1997 2265 2270
13. Y. Kawaura Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model J Gastroenterol 36 9 2001 595 600
14. B.S. Kaur Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion Am J Physiol Gastrointest Liver Physiol 278 6 2000 G1000 G1009
15. F. Zhang Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids Gastroenterology 121 6 2001 1391 1399
16. K.T. Wilson Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas Cancer Res 58 14 1998 2929 2934
17. C.J. Yen Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma Cancer Res 68 8 2008 2632 2640
18. R.F. Souza Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus Gastroenterology 122 2 2002 299 307
19. N.S. Buttar The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study J Natl Cancer Inst 94 6 2002 422 429
20. Y. Nishigaki Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis Dig Dis Sci 41 7 1996 1487 1493
21. M. Quante Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia Cancer Cell 21 1 2012 36 51
22. N.S. Buttar Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus Gastroenterology 122 4 2002 1101 1112
23. L.A. Feagins Mechanisms of oxidant production in esophageal squamous cell and Barrett's cell lines Am J Physiol Gastrointest Liver Physiol 294 2 2008 G411 G417
24. S. Rizvi Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis Cancer Res 70 17 2010 6787 6796
25. S. Song COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett's oesophagus and oesophageal adenocarcinoma Gut 56 11 2007 1512 1521
26. R.C. Fitzgerald Inflammatory gradient in Barrett's oesophagus: implications for disease complications Gut 51 3 2002 316 322
27. R.C. Fitzgerald Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants Gut 50 4 2002 451 459
28. K. Dvorakova Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus Clin Cancer Res 10 6 2004 2020 2028
29. C.P. Wild, and L.J. Hardie Reflux, Barrett's oesophagus and adenocarcinoma: burning questions Nat Rev Cancer 3 9 2003 676 684
30. M.T. Barrett Evolution of neoplastic cell lineages in Barrett oesophagus Nat Genet 22 1 1999 106 109
31. D. Qiao Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation Carcinogenesis 22 6 2001 957 964
32. L.M. Brown, and S.S. Devesa Epidemiologic trends in esophageal and gastric cancer in the United States Surg Oncol Clin N Am 11 2 2002 235 256
33. M. Pera Epidemiology of esophageal adenocarcinoma J Surg Oncol 92 3 2005 151 159
34. L.S. Engel Population attributable risks of esophageal and gastric cancers J Natl Cancer Inst 95 18 2003 1404 1413
35. W.H. Chow Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 90 2 1998 150 155
36. J. Lagergren, R. Bergström, and O. Nyrén Association between body mass and adenocarcinoma of the esophagus and gastric cardia Ann Intern Med 130 11 1999 883 890
37. E.E. Calle, and R. Kaaks Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms Nat Rev Cancer 4 8 2004 579 591
38. B.J. Kendall The risk of Barrett's esophagus associated with abdominal obesity in males and females Int J Cancer 132 9 2013 2192 2199
39. H. Nordenstedt, and H. El-Serag The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992-2006) Scand J Gastroenterol 46 5 2011 597 602
40. A. Steffen Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition Cancer Epidemiol Biomarkers Prev 18 7 2009 2079 2089
41. E.M. Nelsen Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus Clin Gastroenterol Hepatol 10 7 2012 728 734 quiz e61-2
42. H.B. El-Serag Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study Gut 63 2 2014 220 229
43. P. Beddy Association of visceral adiposity with oesophageal and junctional adenocarcinomas Br J Surg 97 7 2010 1028 1034
44. J. Lagergren Influence of obesity on the risk of esophageal disorders Nat Rev Gastroenterol Hepatol 8 6 2011 340 347
45. J.S. Koppman Esophageal motility disorders in the morbidly obese population Surg Endosc 21 5 2007 761 764
46. V. Ortiz Value of heartburn for diagnosing gastroesophageal reflux disease in severely obese patients Obes (Silver Spring) 14 4 2006 696 700
47. M.A. Kuper Dysfunction of the lower esophageal sphincter and dysmotility of the tubular esophagus in morbidly obese patients Obes Surg 19 8 2009 1143 1149 Epub 2009 Jun 10
48. K.R. McQuaid Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia Aliment Pharmacol Ther 34 2 2011 146 165
49. A.M. Ryan Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets Cancer Epidemiol 35 4 2011 309 319 Epub 2011 Apr 5
50. A.G. Renehan, D.L. Roberts, and C. Dive Obesity and cancer: pathophysiological and biological mechanisms Arch Physiol Biochem 114 1 2008 71 83
51. J. Lysaght T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma Br J Surg 98 7 2011 964 974
52. C. Tselepis Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action Oncogene 21 39 2002 6071 6081
53. H.J. Jo Predictable marker for regression of Barrett's esophagus by proton pump inhibitor treatment in Korea J Neurogastroenterol Motil 19 2 2013 210 218
54. O.J. Lee Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis Neoplasia 7 9 2005 854 861
55. A. Damms-Machado, G. Weser, and S.C. Bischoff Micronutrient deficiency in obese subjects undergoing low calorie diet Nutr J 11 34 2012 10.1186/1475-2891-11-34
56. A. Fountoulakis Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus Dig Dis Sci 49 6 2004 914 919
57. S.J. Lee Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors Korean J Gastroenterol 57 5 2011 281 287
58. H.B. El-Serag Abdominal obesity and the risk of Barrett's esophagus Am J Gastroenterol 100 10 2005 2151 2156
59. J.H. Rubenstein Prediction of Barrett's esophagus among men Am J Gastroenterol 108 3 2013 353 362
60. M.C. Otterstatter Esophageal cancer in Canada: trends according to morphology and anatomical location Can J Gastroenterol 26 10 2012 723 727
61. F. Turati A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma Ann Oncol 24 3 2013 609 617
62. M.G. O'Doherty A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP diet and health Study Gut 61 9 2012 1261 1268
63. S.C. Larsson, and A. Wolk Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies Am J Clin Nutr 86 3 2007 556 565
64. D. Aune Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies Ann Oncol 23 4 2012 843 852
65. 2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level Int J Clin Pharmacol Res 22 2 2002 29 35
66. T. Iwao Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C Hepatogastroenterology 42 5 1995 677 682
67. C.R. Haigh Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor Gastroenterology 124 3 2003 615 625
68. S.I. Abdalla Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis Clin Cancer Res 10 14 2004 4784 4792
69. W. Ye Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia J Natl Cancer Inst 96 5 2004 388 396
70. A.P. Weston Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma Am J Gastroenterol 95 2 2000 387 394
71. W.H. Chow An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma Cancer Res 58 4 1998 588 590
72. A.H. Wu Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus Int J Cancer 103 6 2003 815 821
73. A.D. Jones Helicobacter pylori induces apoptosis in Barrett's-derived esophageal adenocarcinoma cells J Gastrointest Surg 7 1 2003 68 76
74. M.D. Gammon Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 89 17 1997 1277 1284
75. S.S. Mirvish Studies on experimental animals involving surgical procedures and/or nitrosamine treatment related to the etiology of esophageal adenocarcinoma Cancer Lett 117 2 1997 161 174
76. M.B. Menke-Pluymers Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group Cancer 72 4 1993 1155 1158
77. M.R. Gray, R.J. Donnelly, and A.N. Kingsnorth The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus Gut 34 6 1993 727 731
78. B. Avidan Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma Am J Gastroenterol 97 8 2002 1930 1936
79. K.E. Bani-Hani, B.K. Bani-Hani, and I.G. Martin Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma World J Gastroenterol 11 43 2005 6807 6814
80. S. Calmels Bacterial formation of N-nitroso compounds from administered precursors in the rat stomach after omeprazole-induced achlorhydria Carcinogenesis 12 3 1991 435 439
81. D. Forman, S. Al-Dabbagh, and R. Doll Nitrates, nitrites and gastric cancer in Great Britain Nature 313 6004 1985 620 625
82. C. Duncan Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate Nat Med 1 6 1995 546 551
83. S.J. Spechler Carcinogenesis at the gastroesophageal junction: free radicals at the frontier Gastroenterology 122 5 2002 1518 1520
84. R.H. Liu, and J.H. Hotchkiss Potential genotoxicity of chronically elevated nitric oxide: a review Mutat Res 339 2 1995 73 89
85. M. Younes Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus Hum Pathol 31 4 2000 434 438
86. M. Younes Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus Hum Pathol 30 11 1999 1309 1313
87. Q. Zhang Autocrine VEGF signalling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway Gastroenterology 146 2 2014 461 472 e6
88. P.C. Konturek Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors Dig Dis Sci 49 7-8 2004 1075 1083
89. B.J. Reid Observer variation in the diagnosis of dysplasia in Barrett's esophagus Hum Pathol 19 2 1988 166 178
90. R.E. Sampliner Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American college of gastroenterology Am J Gastroenterol 93 7 1998 1028 1032
91. M.K. Hong Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus Cancer 75 2 1995 423 429
92. G.Y. Lauwers Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation Mod Pathol 10 12 1997 1201 1208
93. S. Singh Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis Gut 63 8 2014 1229 1237
94. F. Kastelein Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus Clin Gastroenterol Hepatol 11 4 2013 382 388
95. L.C. Hillman Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus Med J Aust 180 8 2004 387 391
96. F.T. Peters Epithelial cell proliferative activity of Barrett's esophagus: methodology and correlation with traditional cancer risk markers Dig Dis Sci 43 7 1998 1501 1506
97. R. Ouatu-Lascar, R.C. Fitzgerald, and G. Triadafilopoulos Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression Gastroenterology 117 2 1999 327 335
98. F.T. Peters Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus Scand J Gastroenterol 35 12 2000 1238 1244
99. H. Garewal Biomarker studies in reversed Barrett's esophagus Am J Gastroenterol 94 10 1999 2829 2833
100. S. Michopoulos Complete regression of Barrett's esophagus with heat probe thermocoagulation: mid-term results Gastrointest Endosc 50 2 1999 165 172
101. J.P. Byrne, G.R. Armstrong, and S.E. Attwood Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation Am J Gastroenterol 93 10 1998 1810 1815
102. L.J. Brandt, R.L. Blansky, and D.R. Kauvar Repeat laser therapy of recurrent Barrett's epithelium: success with anacidity Gastrointest Endosc 41 3 1995 267
103. B.J. Kovacs Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression Gastrointest Endosc 49 5 1999 547 553
104. L.M. Liao Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis Gastroenterology 142 3 2012 442 452 e5; quiz e22-3
105. E.I. Heath Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial J Natl Cancer Inst 99 7 2007 545 557
106. D. Das, A.P. Chilton, and J.A. Jankowski Chemoprevention of oesophageal cancer and the AspECT trial Recent Results Cancer Res 181 2009 161 169
107. E. Ojima Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid Clin Exp Med 2014
108. S. Singh Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis Clin Gastroenterol Hepatol 11 11 2013 1399 1412 e7
109. K.B. Greer Association of insulin and insulin-like growth factors with Barrett's oesophagus Gut 61 5 2012 665 672
110. R.E. Neale Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? Br J Cancer 100 5 2009 795 798
111. M. Pollak Insulin and insulin-like growth factor signaling in neoplasia Nat Rev Cancer 8 12 2008 915 928
112. M.C. Towler, and D.G. Hardie AMP-activated protein kinase in metabolic control and insulin signaling Circ Res 100 3 2007 328 341
113. A. Chak Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus Clin Gastroenterol Hepatol 2014
114. S. Singh Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis Clin Gastroenterol Hepatol 11 6 June 2013 620 629